News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Otavio Freire

Advertisement

Articles by Otavio Freire

Marketing to Professionals: Key Opinion Control

ByOtavio Freire,Jim Zuffoletti
October 1st 2006

Marketing effectively to physicians in today's pharmaceutical industry is more important than ever. No longer can companies rely solely on DTC and sales force efforts to increase drug and therapeutics revenue.

Advertisement

Latest Updated Articles

  • Marketing to Professionals: Key Opinion Control
    Marketing to Professionals: Key Opinion Control

    Published: October 1st 2006 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Augmentin XR Becomes First Approval Under Commissioner’s National Priority Voucher Pilot Program

2

Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases

3

EU Opportunities: How EMA Support Programs Can Slash Drug Market Entry Costs by 90%

4

FDA Approves Waskyra For Treatment of Wiskott-Aldrich Syndrome

5

Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us